ClinicalTrials.gg
RecruitingNCT07851727Updated Nov 4, 2026

Gastric Focused Ultrasound Stimulation

An interventional study of Gastric Focused Ultrasound Stimulation in Gastroparesis and Delayed Gastric Emptying, sponsored by Evan (Huiliang) Wang. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Evan (Huiliang) Wang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Planned enrollment
104th of 136
12 · median 36
Started
2026
with 8 others
No phase
68 of 184
14 open now
Primary completion
2027-06
later than 20 of 40 live
Registered
183rd of 184
by date

Among the 184 studies in Gastroparesis with a site in United States, this one is the 104th largest by planned enrollment of the 136 interventional ones that give a count, is one of 9 that started in 2026, is one of 68 with no phase, reaches primary completion later than 20 of the 40 other live ones, and was the 183rd registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

This randomized, sham-controlled crossover pilot study will evaluate whether noninvasive gastric focused ultrasound stimulation is associated with changes in postprandial gastric electrical activity and gastrointestinal symptoms in adults with gastroparesis or delayed gastric emptying. Participants will complete one active FUS visit and one sham-stimulation visit in randomized order, separated by at least 48 hours. At each visit, electrogastrography will be recorded before and after a standardized liquid nutritional drink, during active or sham stimulation, and during recovery. Gastrointestinal symptoms will be assessed at prespecified time points using the Total Symptom Score questionnaire.

Read the detailed description

This exploratory pilot study will investigate whether noninvasive gastric focused ultrasound (FUS) stimulation is associated with changes in postprandial gastric electrical activity and gastrointestinal symptoms in adult patients with gastroparesis or clinically significant symptoms of delayed gastric emptying.

A total of 12 participants ages 18 to 70 years will complete two study visits in a randomized crossover design. During one visit, participants will receive active gastric focused ultrasound stimulation; during the other visit, they will receive sham stimulation. The order of active and sham stimulation will be randomized. The two visits will be separated by at least 48 hours to reduce potential carryover effects. When possible, visits will be scheduled at a similar time of day.

Participants will fast for at least 6 to 8 hours before each visit, except for water and medications permitted by their treating physician. At each visit, nine electrogastrography (EGG) electrodes will be placed on cleaned skin over the upper abdomen and stomach region. Participants will complete approximately 10 minutes of fasting baseline EGG recording, consume up to two bottles of Ensure or Glucerna nutritional drink within approximately 15 minutes as tolerated, and complete approximately 10 minutes of post-meal EGG monitoring.

Participants will then receive active FUS or sham stimulation according to their randomized visit assignment. Active stimulation will be delivered noninvasively through the abdominal skin over the stomach region using an ultrasound transducer and coupling gel. Active stimulation will use a center frequency of 650 kHz and pulse repetition frequency of 1 kHz. Each pulse will consist of 200 microseconds on and 800 microseconds off, corresponding to a 20% pulse-level duty cycle. Pulsed ultrasound will be delivered in repeated blocks of 500 milliseconds on and 500 milliseconds off throughout a total FUS session of 600 seconds. During the sham condition, transducer placement, coupling gel, device setup, and study procedures will be the same, but no active ultrasound energy will be delivered.

EGG signals will be recorded continuously during stimulation or sham and during approximately 10 minutes of post-stimulation recovery monitoring. Participants will report discomfort, warmth, tingling, nausea, pain, dizziness, or other symptoms. Study procedures may be paused or stopped at any time at the participant's request or if the study team identifies a safety concern.

Gastrointestinal symptom severity will be assessed using the Total Symptom Score questionnaire. The Total Symptom Score sums ratings of nausea, vomiting, early satiety, bloating, postprandial fullness, and abdominal pain. Each symptom is rated from 0 to 4, with a total score ranging from 0 to 24; higher scores indicate worse symptom severity. Symptom ratings will be collected at the past-two-week baseline assessment, immediately before stimulation, after meal consumption, immediately after FUS or sham stimulation, and 30 minutes after stimulation completion.

The study will evaluate EGG signal characteristics, including gastric slow-wave rhythm, dominant frequency, amplitude or power, and percentage of time in normal gastric rhythm, and will compare within-participant changes between active FUS and sham conditions. The study is intended to assess feasibility and preliminary physiological effects and is not designed to establish clinical efficacy.

03

Conditions studied

  • Gastroparesis
  • Delayed Gastric Emptying

Browse trials for

Keywords

  • Electrogastrography
  • Ultrasound
  • Sham-Controlled Study
  • Non-invasive Stimulation
  • Gastric
  • Gastric stimulation
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years.
  • Delayed gastric emptying or gastroparesis diagnosed by a clinician and confirmed by gastric emptying scintigraphy or a gastric emptying breath test.
  • Ability to understand the study procedures, provide , and complete two study visits.
  • Ability to consume the two bottles of Ensure or Glucerna nutritional drink used in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Epilepsy.
  • Cardiac pacemaker or another implanted electronic medical device.
  • Peritoneal dialysis.
  • Daily use of narcotic or opioid medications.
  • Abdominal wall ulcers, open wounds, active infection, or significant skin irritation in the area where the electrogastrography electrodes or focused ultrasound transducer will be placed.
  • Known allergy or to the available Ensure or Glucerna nutritional drinks.
  • Any other medical or safety condition that, in the judgment of the study team, would make participation unsafe.

Medication Restrictions:

Participants using medications that may significantly affect gastric motility or gastric emptying may be rescheduled if those medications were used within the study-defined restriction period. Relevant medications include opioid analgesics, prokinetic agents, anticholinergic or antispasmodic agents, GLP-1 receptor agonists or related medications, and anti-nausea or antiemetic medications that may affect gastrointestinal function. Participants should not discontinue any medically necessary medication without first consulting their treating physician.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Active Gastric Focused Ultrasound Stimulation

    Participants will receive noninvasive gastric focused ultrasound stimulation during one randomized study visit. Participants will undergo fasting baseline EGG recording, consume up to two bottles of a standardized Ensure or Glucerna nutritional drink as tolerated, complete post-meal EGG monitoring, receive active FUS, and complete recovery EGG monitoring and symptom assessments.

    Device: Gastric Focused Ultrasound Stimulation

  • Sham comparator
    Sham Gastric Focused Ultrasound Stimulation

    Participants will undergo the same procedures as during the active FUS visit, including fasting baseline EGG recording, standardized Ensure or Glucerna nutritional drink consumption, transducer placement, ultrasound coupling gel application, device setup, post-meal and recovery EGG monitoring, and symptom assessments. No active ultrasound energy will be delivered during the sham condition.

    Device: Gastric Focused Ultrasound Stimulation

Interventions

  • DeviceGastric Focused Ultrasound Stimulation

    Noninvasive focused ultrasound stimulation will be delivered through the abdominal skin over the stomach region using an ultrasound transducer and coupling gel. Active stimulation will use a center frequency of 650 kHz and a pulse repetition frequency of 1 kHz. Each pulse will consist of 200 microseconds on and 800 microseconds off, corresponding to a 20% pulse-level duty cycle. Pulsed ultrasound will be delivered in repeated blocks of 500 milliseconds on and 500 milliseconds off during a total FUS session of 600 seconds.

06

What researchers measure

Primary outcomes

  1. Change in Gastrointestinal Symptom Severity Measured by Total Symptom Score

    The Total Symptom Score is the sum of participant-reported severity ratings for nausea, vomiting, early satiety, bloating, postprandial fullness, and abdominal pain. Each symptom is rated from 0 (absent) to 4 (extremely severe), yielding a total score ranging from 0 to 24; higher scores indicate greater symptom severity. Within-participant change in Total Symptom Score from immediately before stimulation to 30 minutes after completion of active FUS or sham stimulation will be compared between conditions.

    Time frame: Immediately before stimulation and 30 minutes after completion of active FUS or sham stimulation at each study visit.

  2. Change in Gastric Dominant Frequency Measured by Electrogastrography

    Gastric dominant frequency will be derived from electrogastrography (EGG) recordings and reported in cycles per minute (cpm). Within-participant values during active FUS and sham stimulation will be compared.

    Time frame: At each study visit: 10-min fasting baseline; 10-min post-meal recording before active FUS or sham; 10-min recording during active FUS or sham; and 10-min recovery recording immediately after stimulation.

  3. Change in Gastric EGG Signal Amplitude

    Gastric EGG signal amplitude will be derived from EGG recordings and reported in microvolts (µV). Within-participant values during active FUS and sham stimulation will be compared.

    Time frame: At each study visit: 10-min fasting baseline; 10-min post-meal recording before active FUS or sham; 10-min recording during active FUS or sham; and 10-min recovery recording immediately after stimulation.

  4. Change in Percentage of Time in Normal Gastric Rhythm

    The percentage of analyzable EGG recording time with gastric dominant frequency within the normogastric range of 2 to 4 cycles per minute will be calculated and reported as a percentage. Within-participant values during active FUS and sham stimulation will be compared.

    Time frame: At each study visit: 10-min fasting baseline; 10-min post-meal recording before active FUS or sham; 10-min recording during active FUS or sham; and 10-min recovery recording immediately after stimulation.

07

Study locations

1 of 1 sites recruiting
  • Biomedical Engineering Building
    Austin, Texas 78712, United States
    Recruiting
08

References and documents

Publications

  • Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38. doi: 10.1038/ajg.2012.373. Epub 2012 Nov 13. PubMed 23147521 ↗
  • Cheng LK. Slow wave conduction patterns in the stomach: from Waller's foundations to current challenges. Acta Physiol (Oxf). 2015 Feb;213(2):384-93. doi: 10.1111/apha.12406. Epub 2014 Nov 15. PubMed 25313679 ↗
  • O'Grady G, Gharibans AA, Du P, Huizinga JD. The gastric conduction system in health and disease: a translational review. Am J Physiol Gastrointest Liver Physiol. 2021 Nov 1;321(5):G527-G542. doi: 10.1152/ajpgi.00065.2021. Epub 2021 Sep 22. PubMed 34549598 ↗
  • Javid A, Ilham S, Kiani M. A Review of Ultrasound Neuromodulation Technologies. IEEE Trans Biomed Circuits Syst. 2023 Oct;17(5):1084-1096. doi: 10.1109/TBCAS.2023.3299750. Epub 2023 Nov 21. PubMed 37506009 ↗
  • Bashashati M, Andrews CN, Chen JDZ, McCallum RW, Koch KL. Gastric electrophysiology. Expert Rev Gastroenterol Hepatol. 2026 May;20(5):459-473. doi: 10.1080/17474124.2026.2663975. Epub 2026 Apr 28. PubMed 42018791 ↗
  • Song G, Sun Y, Bashashati M, Quezada A, Sigaroodi S, Sarosiek I, Chen JDZ, McCallum RW. Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. Neurogastroenterol Motil. 2018 Sep;30(9):e13361. doi: 10.1111/nmo.13361. Epub 2018 May 10. PubMed 29745434 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 56 non-industry interventional studies with no phase under Gastroparesis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 9 months is below that.

Counting every sponsor, half of 65 studies reached it within 28 months; a quarter within 11 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 1, 2026
StartActual
Sep 11, 2026
Primary completionEst.
Jun 11, 2027
CompletionEst.
Sep 11, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851727
Lead sponsor
Evan (Huiliang) Wang
Responsible party
Evan (Huiliang) Wang (Assistant Professor, University of Texas at Austin) — Sponsor-investigator
First posted
Oct 1, 2026
Start date
Sep 11, 2026
Primary completion
Jun 11, 2027 (estimated)
Completion
Sep 11, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Mengmeng Yao, Ph.D.
Contact
mmyao1102@gmail.com
5732343390
Huiliang Wang, PhD
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion